Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Podcast | Sexual health in older age

Dr Holly Thomas helps us unpack the needlessly taboo subject of sex and sexual health in women of older age.

Listen now
ADVANCED SEARCH
Log in
Top
Current Oncology Reports

12-03-2025 | Melanoma | Review

Novel Clinical PET Tracers in the Pipeline for Melanoma

Authors: Nora Jaber, Hanna Saadani, Winnie Schats, Else A. Aalbersberg, Marcel P. M. Stokkel

Published in: Current Oncology Reports

Login to get access

Abstract

Purpose

The aim of this review is to provide an overview of novel clinical PET tracers in the pipeline for melanoma. Secondarily, to provide a head-to-head comparison with the current clinical standard used in clinical practice, [18F]FDG, if available.

Recent Findings

[18F]FDG PET/CT has become important in the clinical setting for melanoma as it serves many purposes, but lacks other important qualities due its nonspecific nature. There is an increased clinical need for specific tracers. Many new PET tracers, such as melanin-targeted and antibody-based probes, have been studied in melanoma with the intention of achieving high sensitivity detection of metastases and small lesions.

Summary

There are four main groups of PET tracers in de pipeline for melanoma: melanin-, FAP-, PD-1/PD-L1- and CD8+ T cell-tracers. Melanin-targeted tracers and FAP inhibitors revealed potential for diagnostic application, whilst PD-1/PD-L1 and CD8+ T cell tracers demonstrated potential for response assessment and prediction. In conclusion, research has revealed promising results from current (ongoing) studies; however, more melanoma patients need to be included to further assess the value of these tracers.
Literature
1.
Pyo A, Kim DY, Kim H, Lim D, Kwon SY, Kang SR, et al. Ultrasensitive detection of malignant melanoma using PET molecular imaging probes. Proc Natl Acad Sci U S A. 2020;117:12991–9.CrossRefPubMedPubMedCentral
2.
Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 2022;158:495–503.CrossRefPubMedPubMedCentral
3.
Vercellino L, de Jong D, Dercle L, Hosten B, Braumuller B, Das JP et al. Translating molecules into Imaging-The development of new PET tracers for patients with melanoma. Diagnostics (Basel). 2022;12.
4.
Zhang X, Lin Z, Li M, Gai Y, Zheng H, Fan L, et al. Melanin-targeted [18F]-PFPN PET imaging for prognosticating patients with melanoma. Eur J Nucl Med Mol Imaging. 2023;50:3062–71.CrossRefPubMed
5.
Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.CrossRefPubMed
6.
Seban RD, Nemer JS, Marabelle A, Yeh R, Deutsch E, Ammari S, et al. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Eur J Nucl Med Mol Imaging. 2019;46:2298–310.CrossRefPubMed
7.
Seban RD, Moya-Plana A, Antonios L, Yeh R, Marabelle A, Deutsch E, et al. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. Eur J Nucl Med Mol Imaging. 2020;47:2301–12.CrossRefPubMed
8.
Alauddin MM. Positron emission tomography (PET) imaging with (18)F-based radiotracers. Am J Nucl Med Mol Imaging. 2012;2:55–76.PubMed
9.
10.
Kleynhans J, Ebenhan T, Sathekge MM. Expanding role for Gallium-68 PET imaging in oncology. Semin Nucl Med. 2024.
11.
Lugat A, Bailly C, Chérel M, Rousseau C, Kraeber-Bodéré F, Bodet-Milin C, Bourgeois M. Immuno-PET: design options and clinical proof-of-concept. Front Med (Lausanne). 2022;9:1026083.CrossRefPubMed
12.
Maranduca MA, Branisteanu D, Serban DN, Branisteanu DC, Stoleriu G, Manolache N, Serban IL. Synthesis and physiological implications of melanic pigments. Oncol Lett. 2019;17:4183–7.PubMedPubMedCentral
13.
14.
Zhang X, Li M, Gai Y, Chen J, Tao J, Yang L, et al. 18F-PFPN PET: A new and attractive imaging modality for patients with malignant melanoma. J Nucl Med. 2022;63:1537–43.CrossRefPubMedPubMedCentral
15.
Zhang X, Li M, Lan X, Melanin-Targeted PET. Imaging with 18F-PFPN for identifying gastric metastatic melanoma. Clin Nucl Med. 2022;47:666–7.CrossRefPubMed
16.
Yang Y, Hu S. First-in-humans application of 18F-DMPY2: a prospective melanin-targeted PET probe in malignant melanoma patients. J Nucl Med. 2023;64.
17.
Pyo A, Jung Y-R, Kim D-Y, Min J-J. Comparative evaluation of [18F]DMPY2, [18F]P3BZA and [18 F]FBZA for PET imaging of malignant melanoma in small animal models. J Nucl Med. 2021;62:1471.
18.
Ma X, Wang S, Wang S, Liu D, Zhao X, Chen H, et al. Biodistribution, radiation dosimetry, and clinical application of a melanin-targeted PET probe,18F-P3BZA, in patients. J Nucl Med. 2019;60:16–22.CrossRefPubMed
19.
Su D, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L, Kluger H. Melanocortin 1 receptor (MC1R) expression as a marker of progression in melanoma. Res Sq. 2023.
20.
Marks BM, Block M, Johnson GB, Hruska CB, Pandey MK, Paulsen A et al. MC1R imaging and histology in the targeted imaging of melanoma for alpha-particle radiotherapy (TIMAR1) trial. Cancer Res. 2023;83.
21.
Silvera E, Cabrera M, Camacho X, Tassano M, Giglio J, Trindade V et al. 68Ga-DOTA-G2-Nle-MSH as specific melanoma targeting imaging agent: radiolabelling and early human trial. J Nucl Med. 2023;64.
22.
Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of Cancer. J Nucl Med. 2019;60:801–5.CrossRefPubMedPubMedCentral
23.
Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, et al. Radiation dosimetry and biodistribution of (68)Ga-FAPI-46 PET imaging in Cancer patients. J Nucl Med. 2020;61:1171–7.CrossRefPubMedPubMedCentral
24.
Kaplan İ, Kepenek F, Güzel Y, Can C, Kömek H. The role of 68Ga FAPI-04 and 18F-FDG PET/CT in detecting liver metastases in different types of Cancer. Nuklearmedizin - NuclearMedicine. 2022;62:252–9.
25.
Liu Y, Ding H, Wan Z, Fan D, Huang Z. Malignant melanoma of the external auditory Canal on 68 Ga-FAPI PET/CT. Clin Nucl Med. 2023;48:532–3.CrossRefPubMed
26.
Ou L, Yang X, Liu H, Gong W, Zhang C. Increased68Ga-FAPI activity in malignant melanoma of the nasal cavity. Clin Nucl Med. 2022;47:147–8.CrossRefPubMed
27.
Erol Fenercioǧlu Ö, Beyhan E, Ergül N, Arslan E, Çermik TF. 18F-FDG PET/CT and68Ga-FAPI-4 PET/CT findings of bilateral knee osteoarthritis in a patient with uveal malignant melanoma. Clin Nucl Med. 2022;47:E144–6.CrossRefPubMed
28.
Novruzov F, Mehdi E, Orucova N, Aliyeva G, Valla F, Mammadzada H, et al. Controversies of [68Ga]Ga-FAPI-46 and 2-[18F]FDG findings in metastatic melanoma. Eur J Nucl Med Mol Imaging. 2024;51:609–10.CrossRefPubMed
29.
Mokoala K, Emil N, Lawal I, Antke C, Giesel FL, Sathekge M. [68 Ga]Ga-FAPI versus [18F]F-FDG in malignant melanoma: complementary or counterpoint? Eur J Nucl Med Mol Imaging. 2022;49:2445–6.CrossRefPubMed
30.
Schwenck J, Sonanini D, Seyfried D, Ehrlichmann W, Kienzle G, Reischl G, et al. In vivo imaging of CD8 + T cells in metastatic cancer patients: first clinical experience with simultaneous [89Zr]Zr-Df-IAB22M2C PET/MRI. Theranostics. 2023;13:2408–23.CrossRefPubMedPubMedCentral
31.
Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13:964442.CrossRefPubMedPubMedCentral
32.
He H, Qi X, Fu H, Xu J, Zheng Q, Chen L, et al. Imaging diagnosis and efficacy monitoring by [89Zr]Zr-DFO-KN035 ImmunoPET in patients with PD-L1-positive solid malignancies. Theranostics. 2024;14:392–405.CrossRefPubMedPubMedCentral
33.
Kok IC, Hooiveld JS, van de Donk PP, Giesen D, van der Veen EL, Lub-de Hooge MN, et al. 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 Blockade in cancer. Ann Oncol. 2022;33:80–8.CrossRefPubMed
34.
Rizzetto G, De Simoni E, Molinelli E, Offidani A, Simonetti O. Efficacy of pembrolizumab in advanced melanoma: A narrative review. Int J Mol Sci. 2023;24.
35.
Wang S, Zhu H, Ding J, Wang F, Meng X, Ding L, et al. Positron emission tomography imaging of programmed death 1 expression in Cancer patients using 124I-Labeled Toripalimab: A pilot clinical translation study. Clin Nucl Med. 2021;46:382–8.CrossRefPubMed
36.
Nienhuis PH, Antunes IF, Glaudemans AWJM, Jalving M, Leung D, Noordzij W, et al. 18F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study. J Nucl Med. 2022;63:899–905.CrossRefPubMedPubMedCentral
37.
Donnelly DJ, Smith RA, Morin P, Lipovšek D, Gokemeijer J, Cohen D, et al. Synthesis and biologic evaluation of a novel (18)F-Labeled adnectin as a PET radioligand for imaging PD-L1 expression. J Nucl Med. 2018;59:529–35.CrossRefPubMed
38.
Postow MA, Mauguen A, Frosina D, Jungbluth AA, Busam KJ, Pandit-Taskar N, Assessing. PD-L1 without a biopsy and through PD-L1 PET imaging with 18F-BMS- 986229. J Clin Oncol. 2022;40.
39.
Farwell MD, Gamache RF, Babazada H, Hellmann MD, Harding JJ, Korn R, et al. CD8-Targeted PET imaging of Tumor-Infiltrating T cells in patients with cancer: A phase I First-in-Humans study of 89 Zr-Df-IAB22M2C, a radiolabeled Anti-CD8 minibody. J Nucl Med. 2022;63:720–6.PubMedPubMedCentral
40.
Schwenck J, Sonanini D, Ehrlichmann W, Kienzle G, Reischl G, Krezer P et al. Imaging of CD8 + cytotoxic T-cells by Zr-89- Df-IAB22M2C PET/MRI: first clinical experience in patients with metastatic cancer. Cancer Res. 2022;82.
41.
Postow M, Mauguen A, Farwell M, Gordon M, Hays D, Wong J, et al. Assessing the correlation between cd8 cell pet imaging with 89-zr-crefmirlimab berdoxam and cd8 cell immunohistochemistry in patients with advanced cancer receiving immunotherapy. J Immunother Cancer. 2022;10:A1529.
42.
Kist de Ruijter L, van de Donk PP, Hooiveld-Noeken JS, Giesen D, Elias SG, Lub-de Hooge MN, et al. Whole-body CD8 + T cell visualization before and during cancer immunotherapy: a phase 1/2 trial. Nat Med. 2022;28:2601–10.CrossRefPubMedPubMedCentral
43.
44.
Zhou H, Wang Y, Xu H, Shen X, Zhang T, Zhou X, et al. Noninvasive interrogation of CD8 + T cell effector function for monitoring early tumor responses to immunotherapy. J Clin Invest. 2022;132:e161065.CrossRefPubMedPubMedCentral
45.
Zhang-Yin J, Jublanc C, Aouidad I, Montravers F, Talbot JN. Incidental metastatic melanoma identified on 18F-FDOPA PET/CT with confirmation by histology. Clin Nucl Med. 2020;45:817–8.CrossRefPubMed
46.
Shamim SA, Tripathy S, Rastogi S, Barwad A, Prakash S. Isolated pancreatic metastasis from choroidal melanoma after 10 years of enucleation mimicking neuroendocine tumor on 68Ga-DOTANOC PET/CT. Clin Nucl Med. 2021;46:E21–2.CrossRefPubMed
47.
Broos WAM, Knol RJJ, Zant FMV, Schaper NC, Wondergem M. Incidental findings on 18 F-Fluorocholine PET/CT for parathyroid imaging. World J Nuclear Med. 2022;21:192–9.CrossRef
48.
Manafi-Farid R, Mahini M, Mirshahvalad SA, Fallahi B, Fard-Esfahani A, Emami-Ardekani A, et al. Diagnostic value of [68Ga]Ga-Pentixafor PET/CT in malignant melanoma: A pilot study. Nucl Med Commun. 2024;45:221–8.CrossRefPubMed
49.
Nikaki A, Papadopoulos V, Valotassiou V, Efthymiadou R, Angelidis G, Tsougos I et al. Evaluation of the performance of 18F-Fluorothymidine positron emission tomography/computed tomography (18F-FLT-PET/CT) in metastatic brain lesions. Diagnostics (Basel). 2019;9.
50.
Yeh R, Trager MH, Rizk EM, Finkel GG, Barker LW, Carvajal RD, et al. FLT-PET at 6 weeks predicts response assessed by CT at 12 weeks in melanoma patients treated with pembrolizumab. Clin Nucl Med. 2020;45:267–75.CrossRefPubMedPubMedCentral
51.
Miedema IH, Zwezerijnen GJ, Van Dongen GA, Vugts DJ, Huisman MC, Hoekstra OS et al. Tumor uptake and biodistribution of 89Zirconium-labeled ipilimumab in patients with metastatic melanoma during ipilimumab treatment. Cancer Res. 2019;79.
52.
Oldan JD, Ollila DW, Giglio BC, Smith E, Bouchard DM, Ivanovic M et al. High intratumoral Tryptophan metabolism is a poor predictor of response to pembrolizumab (pembro) in metastatic melanoma (MM): results from a prospective trial using baseline C11-labeled alpha-methyl Tryptophan (C11-AMT) PET imaging for response prediction. J Clin Oncol. 2020;38.
Metadata
Title
Novel Clinical PET Tracers in the Pipeline for Melanoma
Authors
Nora Jaber
Hanna Saadani
Winnie Schats
Else A. Aalbersberg
Marcel P. M. Stokkel
Publication date
12-03-2025
Publisher
Springer US
Published in
Current Oncology Reports
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-025-01659-1

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Video
Image Credits